CDC advises docs to prescribe Tamiflu, Relenza to fight flu

Share this article:
The Centers for Disease Control and Prevention (CDC) is asking doctors not to prescribe two common generic antivirals, amantadine and rimantidine, during the 2005-2006 flu season because recent lab tests showed this winter's predominant flu strain is resistant to the drugs. The CDC has tested 120 influenza A (H3N2) virus isolates and found that 91% were resistant to amantadine and rimantadine. This represents a sharp increase from last year when only 11 percent of isolates tested were resistant and 1.9 percent were resistant the year before that. “This is certainly unexpected news as we now have to remove a few tools from our tool box that we use to combat influenza,” said Julie Gerberding, CDC director. The CDC is recommending Roche’s Tamiflu (oseltamivir) and GlaxoSmithKline’s Relenza (zanamivir) be prescribed if an antiviral medication is needed for the treatment or prevention of influenza.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.